The National Centre for Pharmaco-economics (NCPE) have completed their evaluation of Ocrelizumab for the treatment of adult patients with early primary progressive Multiple Sclerosis (PPMS), and have sent the final report to the HSE CPU. The web summary is now available on the National Centre for Pharmacoeconomics website. >> Read more
The NCPE report recommends that ocrelizumab for the treatment of adult patients with early PPMS not be considered for reimbursement.
MS Ireland have secured a meeting with the Minister for Health, Simon Harris in relation to the issues of access to medicines.